Induced stem cells

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Health, Genetics, Stem cells, Oncology, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cloning, Developmental biology, Hematopoietic stem cell transplantation, Organ transplantation, Regenerative Medicine Advanced Therapy

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:

Key Points: 
  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:
    2021 Wedbush PacGrow Healthcare Virtual Conference, panel: So Let it Be (Re)Written - Updates in Gene Modulation at 9:10 a.m.
  • ET on Tuesday, August 10
    Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.
  • Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
  • Magenta is based in Cambridge, Mass.

Cellino Appoints Industry Pioneer Robert J. Palay to the Board

Retrieved on: 
Tuesday, August 3, 2021
Technology, Surgery, Medical devices, General Health, Science, Genetics, Biotechnology, Health, Other Science, Research, Other Technology, Software, Other Health, Hardware, Pharmaceutical, Stem cells, Oncology, Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Cloning, Developmental biology, Induced pluripotent stem cell, Cellino, IPSC

Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.

Key Points: 
  • Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20210803005032/en/
    Mr. Palay is one of the pioneers of the induced pluripotent stem cell (iPSC) industry.
  • "We are pleased to welcome Robert to the Cellino Board," said Nabiha Saklayen, Ph.D, CEO & Co-Founder, Cellino.
  • "I am thrilled to join the Cellino Board," said Robert J. Palay.

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, T cells, Stem cells, Regulatory T cell, IPSCS, Induced pluripotent stem cell

LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.

Key Points: 
  • LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.
  • "We are delighted to welcome Tracey to Quell.
  • She brings impressive drug discovery experience working with a wide range of cell therapy platforms, including induced pluripotent stem cells (iPSCs), Treg and T-effector cells and genetic engineering," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • "We believe that Tracey's extensive technical and therapeutic expertise enhances our industry leading engineered Treg cell therapy development capabilities and reinforces our proven operational competency.

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, Stem cells, T cells, IPSCS, Regulatory T cell, Induced pluripotent stem cell

LONDON and BOSTON, July 29, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer. Dr. Lodie brings to Quell more than 20 years of experience in the biopharmaceutical industry focused on the discovery and development of cell therapies and novel biologics in the areas of autoimmunity, transplant biology and immune-oncology.

Key Points: 
  • "We are delighted to welcome Tracey to Quell.
  • She brings impressive drug discovery experience working with a wide range of cell therapy platforms, including induced pluripotent stem cells (iPSCs), Treg and T-effector cells and genetic engineering," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • "We believe that Tracey's extensive technical and therapeutic expertise enhances our industry leading engineered Treg cell therapy development capabilities and reinforces our proven operational competency.
  • Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases.

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Mesenchymal stem cell, Adult stem cell, Induced stem cells, Shimon Slavin

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).

National STEM Scholars Announced for 2021

Retrieved on: 
Thursday, July 22, 2021
Articles, Branches of biology, Biology, Induced stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell, Stem, Science, technology, engineering, and mathematics, Western Kentucky University

STEM Scholars convene on WKU's campus for a week of advanced STEM training and finalize their projects with input from their STEM Scholar class colleagues.

Key Points: 
  • STEM Scholars convene on WKU's campus for a week of advanced STEM training and finalize their projects with input from their STEM Scholar class colleagues.
  • The 2021 National STEM Scholar class was hosted by The Gatton Academy May 30th to June 5th on the campus of WKU in Bowling Green, KY.
  • By June 2021, STEM Scholars will have directly and indirectly impacted an estimated 66,000 middle school students in the U.S.
  • The National Stem Cell Foundation is a 501(c)3 non-profit organization that funds adult stem cell and regenerative medicine research, connects children with limited resources to clinical trials for rare diseases and underwrites the National STEM Scholar Program for middle school science teachers inspiring the next generation of STEM pioneers nationwide.

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

Retrieved on: 
Friday, July 16, 2021
Life sciences, Biology, Biotechnology, Induced stem cells, Developmental biology, Stem cells, IPSCS, Biopharmaceutical, Cellular differentiation, Induced pluripotent stem cell

The archived webcast will be available on the Company's website beginning approximately two hours after the event.

Key Points: 
  • The archived webcast will be available on the Company's website beginning approximately two hours after the event.
  • Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.
  • Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support the Development of Personalized Therapeutics

Retrieved on: 
Thursday, July 15, 2021
Life sciences, Biology, Articles, Biotechnology, Pharmaceutical industry, Cloning, Induced stem cells, Developmental biology, Stem cell, Good manufacturing practice, Biopharmaceutical

LOS ANGELES, July 15, 2021 /PRNewswire/ -- Generate Life Sciences (Generate) today announced the establishment of its Good Manufacturing Practice (GMP) facility in La Jolla, Calif. which will enable end-to-end manufacturing for newborn stem cell biologics.

Key Points: 
  • LOS ANGELES, July 15, 2021 /PRNewswire/ -- Generate Life Sciences (Generate) today announced the establishment of its Good Manufacturing Practice (GMP) facility in La Jolla, Calif. which will enable end-to-end manufacturing for newborn stem cell biologics.
  • This facility will represent a big step in the evolution of Generate and its broader life sciences platform adding the role of a personalized therapeutics developer with in-house manufacturing capabilities to its core international donor gamete, genetics service and newborn stem cell preservation business.
  • The new Generate facility has been designed to harness these inherent properties to maximize bioprocessing efficiency and manufacture at scale.
  • "The La Jolla GMP facility will be a crucial addition to Generate's vision for our newborn stem cell operation," said Jaime Shamonki, MD, Generate's Chief Medical Officer.

Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates

Retrieved on: 
Saturday, June 26, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Cell biology, Developmental biology, Induced pluripotent stem cell, IPSCS, Immunosuppression

SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs).

Key Points: 
  • SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs).
  • The transplanted cells were induced pluripotent stem cells (iPSCs) with Sanas hypoimmune gene modifications that enable immune evasion.
  • Sanas hypoimmune (HIP) platforms goal is to eliminate the need for immunosuppression by cloaking cells from immune recognition.
  • Sana Biotechnology and the Sana Biotechnology logo are trademarks of Sana Biotechnology, Inc. or its subsidiaries.

Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021

Retrieved on: 
Saturday, June 26, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Induced stem cells, Immune system, Natural killer cell, Induced pluripotent stem cell, Cell therapy, IPSCS

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.

Key Points: 
  • CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.
  • Alphageneron is also planning a Phase I clinical Combination trial with Metastatic Colorectal cancer withallogeneic donor genetically edited NK cell therapy, (ANKASTIM) in the United States.
  • To register for this virtual event click www.roth.com/healthcareprivateday or please contact Gerald Roger, c/o Trinity Capital Advisers Tel.
  • Alphageneron is also developing allogeneic Induced pluripotent stem cells (iPSCs) CAR-engineered NK (CAR NK) cells to an undisclosed target.